A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
Stopped Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in the study.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
- BIOLOGICAL: RSV MAT
- DRUG: Placebo
Sponsor
GlaxoSmithKline